Curis (CRIS) Interest & Investment Income (2010 - 2026)
Curis' (CRIS) quarterly Interest & Investment Income came in at $77000.0 in Q1 2026, down 17.2% YoY from $93000.0 in Q1 2025, and up 50.98% on a QoQ basis from $51000.0 in Q4 2025.
Curis (CRIS) Interest & Investment Income (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Interest & Investment Income data on file, last reported at $77000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 17.2% year-over-year to $77000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $300000.0 (up 146.08% YoY) and the FY2025 annual result came in at $316000.0, up 237.99% from the prior year.
- Interest & Investment Income climbed to $77000.0 in Q1 2026, from $51000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $1.5 million in Q4 2022 to a low of -$1.8 million in Q4 2024.
- A 5-year average of $122941.2 and a median of $93000.0 in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income sank 1833.33% — and 2024, when it surged 10114.29%.
- Tracing CRIS's Interest & Investment Income over 5 years: stood at $1.5 million in 2022, then plunged by 55.34% to $665000.0 in 2023, then tumbled by 366.17% to -$1.8 million in 2024, then soared by 102.88% to $51000.0 in 2025, then soared by 50.98% to $77000.0 in 2026.
- The last three Interest & Investment Income figures came in at $77000.0 (Q1 2026), $51000.0 (Q4 2025), and $80000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Curis | 3.27 Mn | -2.35 Mn | - | 62,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77,000.00 |
| Dec 31, 2025 | 51,000.00 |
| Sep 30, 2025 | 80,000.00 |
| Jun 30, 2025 | 92,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Dec 31, 2024 | -1.77 Mn |
| Sep 30, 2024 | 325,000.00 |
| Jun 30, 2024 | 701,000.00 |
| Mar 31, 2024 | 109,000.00 |
| Dec 31, 2023 | 665,000.00 |
| Sep 30, 2023 | 101,000.00 |
| Jun 30, 2023 | -7,000.00 |
| Mar 31, 2023 | 195,000.00 |
| Dec 31, 2022 | 1.49 Mn |
| Sep 30, 2022 | 335,000.00 |
| Jun 30, 2022 | -104,000.00 |
| Mar 31, 2022 | -342,000.00 |
| Dec 31, 2021 | -106,000.00 |
| Jun 30, 2021 | 6,000.00 |
| Mar 31, 2021 | 46,000.00 |